A new study suggests that sildenafil, commonly used for erectile dysfunction, may interfere with cancer spread. Experts explain why the findings are promising but far from a proven treatment
It might sound surprising, but the idea that a drug developed for erectile dysfunction could one day help fight cancer is real.
Some of the biggest advances in medicine have come from finding new uses for old drugs, and a recent line of research is bringing this possibility into focus once again.
An emerging area of interest is sildenafil, the active ingredient in Viagra, which is now being studied for its potential role in slowing the spread of cancer.
What the latest research suggests
A recent study by researchers at the Weizmann Institute of Science in Israel found that sildenafil may interfere with the way cancer cells use cholesterol.
This is significant because cholesterol plays a key role in helping cancer cells detach from the original tumour and spread to distant organs.
Since metastasis is the leading cause of death from cancer, even a small delay or disruption in this process could have meaningful clinical implications.
“These findings are scientifically exciting because they explore how an existing drug might affect cancer biology,” says Dr Saphalta Baghmar, Senior Consultant, Medical Oncology, Amrita Hospital, Faridabad.
Why metastasis matters
Cancer becomes far more difficult to treat once it spreads beyond its original site. Metastasis is responsible for the majority of cancer-related deaths, making it a critical focus of ongoing research.
More from Lifestyle“Any strategy that can delay or halt metastasis deserves serious scientific attention,” explains Dr Baghmar. “However, it is equally important to understand where the evidence stands at present.”
What the study does not prove
While the findings have generated interest, they come from laboratory and preclinical studies. This means the results have not yet been tested in humans.
“These results are promising, but they do not prove that sildenafil can prevent or treat cancer in patients,” Dr Baghmar clarifies. “Before any such claim can be made, the drug must go through well-designed clinical trials.”
She adds that these trials are essential to establish safety, effectiveness, correct dosage and the types of cancers that may benefit from such treatment.
The growing interest in drug repurposing
Within oncology, drug repurposing has gained considerable traction. Using existing drugs for new indications can shorten the time it takes to bring treatments to patients, since their safety profiles are often already well understood.
“Drug repurposing is an important area of research because it can potentially speed up access to therapies,” says Dr Baghmar. “But scientific enthusiasm must always be guided by strong clinical evidence.”
A word of caution for patients
Experts strongly advise against self-medication or using sildenafil with the expectation of preventing cancer or stopping its spread.
“Patients should not start taking sildenafil for cancer prevention or treatment outside of a clinical setting,” warns Dr Baghmar. “Like any prescription medication, it has side effects and can interact with other drugs, particularly those used for heart conditions.”
Misinterpretation of early research findings can lead to unsafe practices, making it crucial for patients to rely on medical guidance.
The bottom line
The study offers a promising lead for future cancer research, but it is far from being a proven treatment.
“At this stage, sildenafil should be viewed as a potential research direction rather than a clinical solution,” concludes Dr Baghmar. “As oncologists, we must follow the evidence, not the headlines, and continue working towards safer and more effective treatments for our patients.”
For now, the findings highlight the potential of scientific innovation, while reinforcing the importance of patience and rigorous testing in the journey from laboratory discovery to real-world treatment.
